` TRDA (Entrada Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

TRDA
vs
S&P 500

Over the past 12 months, TRDA has underperformed S&P 500, delivering a return of -37% compared to the S&P 500's +14% growth.

Stocks Performance
TRDA vs S&P 500

Loading
TRDA
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
TRDA vs S&P 500

Loading
TRDA
S&P 500
Difference
www.alphaspread.com

Performance By Year
TRDA vs S&P 500

Loading
TRDA
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Entrada Therapeutics Inc vs Peers

S&P 500
TRDA
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Entrada Therapeutics Inc
Glance View

Market Cap
419.6m USD
Industry
Biotechnology

Entrada Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 114 full-time employees. The company went IPO on 2021-10-29. The firm's EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its EEV Platform, Entrada is building a development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular diseases, immunology, oncology and diseases of the central nervous system. The firm's lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD), and a follow-on program targeting myotonic dystrophy type 1 (DM1). DMD is a monogenic X-linked disease caused by mutations in the DMD gene.

TRDA Intrinsic Value
4.91 USD
Overvaluation 55%
Intrinsic Value
Price
Back to Top